Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNAmix is a veterinary DNA vaccine developed by Vaxxinova for the aquaculture industry, specifically for the protection of Atlantic salmon (*Salmo salar*) against Salmon Pancreas Disease (SPD) and Salmon Rickettsial Septicaemia (SRS). The vaccine utilizes a DNA plasmid platform to deliver genetic sequences encoding specific viral or bacterial antigens—such as the structural proteins of Salmonid Alphavirus (SAV) or antigens from *Piscirickettsia salmonis*. Upon intramuscular injection, the host's myocytes take up the plasmids and express the encoded proteins, which are then presented to the immune system to elicit both cell-mediated and humoral immunity. This technology offers a significant advantage over traditional oil-adjuvanted vaccines by reducing internal organ adhesions and melanosis while providing robust, long-term protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DNAmix.